Does the media prefer VRTX or AMZN?

In the previous week, Amazon.com had 258 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 277 mentions for Amazon.com and 19 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.01 beat Amazon.com's score of 0.67 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Amazon.com 163 Very Positive mention(s) 37 Positive mention(s) 37 Neutral mention(s) 27 Negative mention(s) 12 Very Negative mention(s) Positive

Does the media favor AXSM or VRTX?

In the previous week, Vertex Pharmaceuticals had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 19 mentions for Vertex Pharmaceuticals and 11 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Vertex Pharmaceuticals' score of 1.01 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer VRTX or CRSP?

In the previous week, Vertex Pharmaceuticals had 9 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Vertex Pharmaceuticals and 10 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.01 beat CRISPR Therapeutics' score of 0.57 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive CRISPR Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings & valuation, VRTX or GOOG?

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vertex Pharmaceuticals $12.59B 10.51 $3.95B $17.18 30.34 Alphabet $402.84B 9.96 $132.17B $19.91 16.48

Does the media prefer VRTX or GOOG?

In the previous week, Alphabet had 188 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 207 mentions for Alphabet and 19 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.01 beat Alphabet's score of 0.87 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Alphabet 124 Very Positive mention(s) 20 Positive mention(s) 34 Neutral mention(s) 21 Negative mention(s) 8 Very Negative mention(s) Positive

Does the media prefer ISRG or VRTX?

In the previous week, Intuitive Surgical had 11 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 30 mentions for Intuitive Surgical and 19 mentions for Vertex Pharmaceuticals. Intuitive Surgical's average media sentiment score of 1.09 beat Vertex Pharmaceuticals' score of 1.01 indicating that Intuitive Surgical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intuitive Surgical 23 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Vertex Pharmaceuticals (VRTX) Competitors

$521.64 -7.26 (-1.37%)

As of 01:33 PM Eastern

Compare

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

Should you buy Vertex Pharmaceuticals stock or one of its competitors? Vertex Pharmaceuticals's main competitors and comparable companies include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Alphabet (GOOG), and Intuitive Surgical (ISRG). Companies are selected based on similarities in market, industry, and size.

How does Vertex Pharmaceuticals compare to Amazon.com?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amazon.com (NASDAQ:AMZN) are related large-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Amazon.com's net margin of 17.44%. Vertex Pharmaceuticals' return on equity of 23.09% beat Amazon.com's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Amazon.com	17.44%	18.00%	8.97%

Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Amazon.com is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.59B	10.51	$3.95B	$17.18	30.34
Amazon.com	$775.68B	3.50	$77.67B	$12.43	20.26

Vertex Pharmaceuticals currently has a consensus target price of $569.52, indicating a potential upside of 9.26%. Amazon.com has a consensus target price of $323.26, indicating a potential upside of 28.34%. Given Amazon.com's stronger consensus rating and higher possible upside, analysts clearly believe Amazon.com is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Amazon.com	0 Sell rating(s)	2 Hold rating(s)	56 Buy rating(s)	1 Strong Buy rating(s)	2.98

In the previous week, Amazon.com had 258 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 277 mentions for Amazon.com and 19 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.01 beat Amazon.com's score of 0.67 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Amazon.com	163 Very Positive mention(s)	37 Positive mention(s)	37 Neutral mention(s)	27 Negative mention(s)	12 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Amazon.com has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.2% of Amazon.com shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of Amazon.com shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals and Amazon.com tied by winning 8 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Axsome Therapeutics' net margin of -24.68%. Vertex Pharmaceuticals' return on equity of 23.09% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

In the previous week, Vertex Pharmaceuticals had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 19 mentions for Vertex Pharmaceuticals and 11 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Vertex Pharmaceuticals' score of 1.01 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.20	-$183.17M	-$3.75	N/A
Vertex Pharmaceuticals	$12.59B	10.51	$3.95B	$17.18	30.34

Axsome Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $267.60, suggesting a potential upside of 27.61%. Vertex Pharmaceuticals has a consensus price target of $569.52, suggesting a potential upside of 9.26%. Given Axsome Therapeutics' higher possible upside, research analysts plainly believe Axsome Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Vertex Pharmaceuticals beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Vertex Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.59B	10.51	$3.95B	$17.18	30.34
CRISPR Therapeutics	$3.51M	1,483.76	-$581.60M	-$4.76	N/A

Vertex Pharmaceuticals has a net margin of 35.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. Vertex Pharmaceuticals' return on equity of 23.09% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Vertex Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Vertex Pharmaceuticals had 9 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Vertex Pharmaceuticals and 10 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.01 beat CRISPR Therapeutics' score of 0.57 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
CRISPR Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Vertex Pharmaceuticals presently has a consensus price target of $569.52, suggesting a potential upside of 9.26%. CRISPR Therapeutics has a consensus price target of $68.06, suggesting a potential upside of 26.35%. Given CRISPR Therapeutics' higher possible upside, analysts clearly believe CRISPR Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Summary

Vertex Pharmaceuticals beats CRISPR Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Alphabet?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alphabet (NASDAQ:GOOG) are related large-cap companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.59B	10.51	$3.95B	$17.18	30.34
Alphabet	$402.84B	9.96	$132.17B	$19.91	16.48

Alphabet has a net margin of 54.77% compared to Vertex Pharmaceuticals' net margin of 35.00%. Alphabet's return on equity of 51.32% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Alphabet	54.77%	51.32%	35.42%

Vertex Pharmaceuticals currently has a consensus target price of $569.52, indicating a potential upside of 9.26%. Alphabet has a consensus target price of $415.55, indicating a potential upside of 26.64%. Given Alphabet's stronger consensus rating and higher possible upside, analysts plainly believe Alphabet is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Alphabet	0 Sell rating(s)	4 Hold rating(s)	30 Buy rating(s)	6 Strong Buy rating(s)	3.05

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.3% of Alphabet shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 13.0% of Alphabet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Alphabet has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

In the previous week, Alphabet had 188 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 207 mentions for Alphabet and 19 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.01 beat Alphabet's score of 0.87 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Alphabet	124 Very Positive mention(s)	20 Positive mention(s)	34 Neutral mention(s)	21 Negative mention(s)	8 Very Negative mention(s)	Positive

Summary

Alphabet beats Vertex Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Intuitive Surgical had 11 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 30 mentions for Intuitive Surgical and 19 mentions for Vertex Pharmaceuticals. Intuitive Surgical's average media sentiment score of 1.09 beat Vertex Pharmaceuticals' score of 1.01 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	23 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.00% compared to Intuitive Surgical's net margin of 28.45%. Vertex Pharmaceuticals' return on equity of 23.09% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.45%	16.91%	14.83%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

Vertex Pharmaceuticals has higher revenue and earnings than Intuitive Surgical. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$11.03B	11.24	$2.86B	$8.73	40.21
Vertex Pharmaceuticals	$12.59B	10.51	$3.95B	$17.18	30.34

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Intuitive Surgical currently has a consensus price target of $508.68, indicating a potential upside of 44.91%. Vertex Pharmaceuticals has a consensus price target of $569.52, indicating a potential upside of 9.26%. Given Intuitive Surgical's higher probable upside, research analysts clearly believe Intuitive Surgical is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.68
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96

Intuitive Surgical has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Summary

Vertex Pharmaceuticals beats Intuitive Surgical on 9 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRTX vs. The Competition

Export

Metric	Vertex Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$132.30B	$3.87B	$7.16B	$12.78B
Dividend Yield	N/A	3.60%	2.54%	9.15%
P/E Ratio	30.34	13.22	271.88	25.30
Price / Sales	10.51	1,619.38	700.01	108.13
Price / Cash	31.07	108.60	77.07	52.39
Price / Book	7.09	16.21	10.86	6.36
Net Income	$3.95B	-$22.81M	$3.48B	$358.07M
7 Day Performance	-6.37%	0.56%	-0.82%	-0.05%
1 Month Performance	5.08%	5.75%	2.80%	-0.94%
1 Year Performance	31.47%	46.72%	21.60%	11.95%

Vertex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRTX Vertex Pharmaceuticals	3.8434 of 5 stars	$521.64 -1.4%	$569.52 +9.2%	+33.8%	$132.40B	$12.59B	30.36	6,400	Positive News
AMZN Amazon.com	4.9116 of 5 stars	$258.51 flat	$323.26 +25.0%	+9.0%	$2.79T	$716.92B	20.80	1,576,000	Trending News
AXSM Axsome Therapeutics	4.3257 of 5 stars	$206.68 flat	$267.60 +29.5%	+60.7%	$10.83B	$638.50M	N/A	380	Positive News
CRSP CRISPR Therapeutics	2.7549 of 5 stars	$55.79 flat	$68.06 +22.0%	+1.3%	$5.39B	$3.51M	N/A	460
GOOG Alphabet	4.8611 of 5 stars	$335.31 flat	$415.55 +23.9%	+43.2%	$4.10T	$402.84B	16.84	190,200	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRTX) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

How does Vertex Pharmaceuticals compare to Amazon.com?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Summary

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

How does Vertex Pharmaceuticals compare to Amazon.com?

Is VRTX or AMZN more profitable?

Which has preferable earnings and valuation, VRTX or AMZN?

Do analysts recommend VRTX or AMZN?

Does the media prefer VRTX or AMZN?

Which has more volatility & risk, VRTX or AMZN?

Do institutionals & insiders have more ownership in VRTX or AMZN?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Is AXSM or VRTX more profitable?

Does the media favor AXSM or VRTX?

Do institutionals and insiders hold more shares of AXSM or VRTX?

Which has stronger valuation and earnings, AXSM or VRTX?

Which has more volatility and risk, AXSM or VRTX?

Do analysts recommend AXSM or VRTX?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Which has stronger earnings and valuation, VRTX or CRSP?

Is VRTX or CRSP more profitable?

Which has more volatility & risk, VRTX or CRSP?

Do institutionals & insiders believe in VRTX or CRSP?

Does the media prefer VRTX or CRSP?

Do analysts recommend VRTX or CRSP?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Which has stronger earnings & valuation, VRTX or GOOG?

Is VRTX or GOOG more profitable?

Do analysts recommend VRTX or GOOG?

Do institutionals and insiders believe in VRTX or GOOG?

Which has more volatility and risk, VRTX or GOOG?

Does the media prefer VRTX or GOOG?

Summary

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Does the media prefer ISRG or VRTX?

Is ISRG or VRTX more profitable?

Which has better valuation and earnings, ISRG or VRTX?

Do insiders and institutionals have more ownership in ISRG or VRTX?

Do analysts recommend ISRG or VRTX?

Which has more risk & volatility, ISRG or VRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools